Author： Subbarao Padmaja Ratjen Felix
Publisher： Humana Press, Inc
ISSN： 1080-0549
Source： Clinical Reviews in Allergy and Immunology, Vol.31, Iss.2-3, 2006-06, pp. : 209-218
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Inhaled β-agonists are commonly prescribed for the treatment of wheezing disorders in infants and children. Despite this, there are concerns that these medications have potentially detrimental effects on lung health and symptoms. We will review the ontogeny of β-agonist receptor and smooth muscle development from fetal life through infancy and childhood as well as the evidence supporting the clinical utility of β-agonists in wheezing infants and asthmatic children. Finally, the potential detrimental effects of long-and short-acting β-agonists in infants and children are discussed.
Related content
β2-Agonists and exercise-induced asthma
By Anderson Sandra Caillaud Corinne Brannan John
Clinical Reviews in Allergy and Immunology, Vol. 31, Iss. 2-3, 2006-06 ,pp. :
Access to resources
Recommend
Clinical concerns with inhaled β2-agonists: Adult asthma
By Cockcroft D.
Clinical Reviews in Allergy and Immunology, Vol. 31, Iss. 2-3, 2006-06 ,pp. :
Clinical Reviews in Allergy and Immunology, Vol. 31, Iss. 2-3, 2006-06 ,pp. :
β2-Agonists and bronchial hyperresponsiveness
Clinical Reviews in Allergy and Immunology, Vol. 31, Iss. 2-3, 2006-06 ,pp. :
β2-Agonists at the olympic games
Clinical Reviews in Allergy and Immunology, Vol. 31, Iss. 2-3, 2006-06 ,pp. :